908 Devices | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 14.01 M

Revenue: As of FY2025 Q3, the actual value is USD 14.01 M, beating the estimate of USD 13.52 M.

EPS: As of FY2025 Q3, the actual value is USD -0.41, missing the estimate of USD -0.16.

EBIT: As of FY2025 Q3, the actual value is USD -17.43 M.

Total Revenue: $38.8 million for the nine months ended September 30, 2025, compared to $33.4 million for the same period in 2024, representing a 16% increase.
Product Revenue: $28.95 million for the nine months ended September 30, 2025, compared to $24.996 million for the same period in 2024, representing a 16% increase.
Service and Contract Revenue: $9.867 million for the nine months ended September 30, 2025, compared to $8.407 million for the same period in 2024, representing a 17% increase.

Total Cost of Revenue: $19.548 million for the nine months ended September 30, 2025, compared to $15.576 million for the same period in 2024, representing a 25% increase.
Product Cost of Revenue: $15.338 million for the nine months ended September 30, 2025, compared to $11.423 million for the same period in 2024, representing a 34% increase.
Service and Contract Cost of Revenue: $4.210 million for the nine months ended September 30, 2025, compared to $4.153 million for the same period in 2024, representing a 1% increase.

Total Gross Profit: $19.269 million for the nine months ended September 30, 2025, compared to $17.827 million for the same period in 2024, representing an 8% increase.
Product Gross Profit: $13.612 million for the nine months ended September 30, 2025, compared to $13.573 million for the same period in 2024, representing a 0.3% increase.
Service and Contract Gross Profit: $5.657 million for the nine months ended September 30, 2025, compared to $4.254 million for the same period in 2024, representing a 33% increase.

Research and Development: $12.071 million for the nine months ended September 30, 2025, compared to $11.088 million for the same period in 2024, representing a 9% increase.
Selling, General and Administrative: $29.712 million for the nine months ended September 30, 2025, compared to $29.001 million for the same period in 2024, representing a 2% increase.
Change in Fair Value of Contingent Consideration: $19.999 million for the nine months ended September 30, 2025, compared to - $12.141 million for the same period in 2024.
Goodwill Impairment: $0 for the nine months ended September 30, 2025, compared to $30.523 million for the same period in 2024.

Interest Income: $3.114 million for the nine months ended September 30, 2025, compared to $3.741 million for the same period in 2024, representing a 17% decrease.
Income from Transition Services Agreement, Net: $2.073 million for the nine months ended September 30, 2025.
Other Expense, Net: - $0.229 million for the nine months ended September 30, 2025, compared to - $0.213 million for the same period in 2024.

Net Loss from Continuing Operations: - $37.655 million for the nine months ended September 30, 2025, compared to - $37.116 million for the same period in 2024.
Net Income (Loss) from Discontinued Operations, Net of Tax: $52.970 million for the nine months ended September 30, 2025, compared to - $15.644 million for the same period in 2024.
Net Income (Loss): $15.315 million for the nine months ended September 30, 2025, compared to - $52.760 million for the same period in 2024.

The company plans to grow its device sales through multiple strategies including expanding sales efforts domestically and globally, and continuing to enhance the underlying technology and applications for its handheld devices.
The company expects consumables and service revenue to increase in future periods as its installed base grows and it is able to generate recurring sales.

The company completed the sale of its Desktop Portfolio to Repligen on March 4, 2025, which represents a strategic shift that will have a major effect on its business.
The company entered into a Transition Services Agreement with Repligen to facilitate the transition of the Desktop Portfolio, which is expected to be substantially completed by June 30, 2026.

The company expects that its cash and cash equivalents and revenue from product and service will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the condensed consolidated financial statements.